Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.70 |
| ▸ | DPYD | Q12882 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL15174408 | 1.00 | ATAD2 (0.70) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL18229756 | 0.92 | ATAD2 (0.59) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL29281739 | 0.89 | ATAD2 (0.70) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL17144680 | 0.88 | ATAD2 (0.54) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL29669526 | 0.84 | — | — | |
| Thymine SCHEMBL15323914 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL750450 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL17201833 | 0.84 | ATAD2 (1.00) | ATAD2DPYDALDH1A1LMNAGAA | |
| Thymine SCHEMBL5235 | 0.84 | — | — | |
| Pyrimidine SCHEMBL29014623 | 0.82 | ATAD2 (0.46) | ATAD2GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNAimmune, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118302181-A | Multigang TP53 and PAN-RAS mRNA cancer vaccine | 达冕生物有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4388017-A1 | COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR | Rudd, Christopher E. (CA) | 2024-06-26 | — | — | EP | disclosed |
| EP-4384214-A2 | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | Rnaimmune, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118119930-A | Compositions and methods for mRNA vaccines against novel coronavirus infection | 达冕生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118099177-A | Integrated photodetector with direct combined pixels | 宽腾矽公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097259-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097894-A1 | COMPOSITIONS AND METHODS OF RIBONUCLEIC ACID VACCINES ENCODING NYE-SO-1 | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4351615-A2 | MULTIPLEXED TP53 AND PAN-RAS MRNA CANCER VACCINES | Rnaimmune, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-6495671-B1 | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use | ISIS PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020187479-A1 | In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads | SYNGENTA PARTICIPATIONS AG (CH) | 2002-12-12 | — | — | US | disclosed |
| US-6403314-B1 | PREDICTING, ANALYZING, AND STORING STABILITIES; DATA PROCESSING | AGILENT TECHNOLOGIES, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1206580-A1 | IMPROVED METHOD FOR NUCLEOTIDE DETECTION AND DEVICES USED THEREIN | Dot Diagnostics B.V. (NL) | 2002-05-22 | — | — | EP | disclosed |
| US-6235886-B1 | OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| WO-2001018241-A1 | IMPROVED METHOD FOR NUCLEOTIDE DETECTION AND DEVICES USED THEREIN | DOT DIAGNOSTICS B.V. (NL) | 2001-03-15 | — | — | WO | disclosed |
| US-5906918-A | QUANTITATING BASE MODIFICATIONS IN SAMPLE DNA BY ENDONUCLEASE DIGESTION TO DINUCLEOSIDE MONOPHOSPHATES, DEPHOSPHORYLATION, LABELING SAMPLE AND INTERNAL STANDARD DNA, ADDING COMIGRATING CARRIERS, SEPARATING SAMPLE/CARRIER FROM STANDARD/CARRIER | HEALTH RESEARCH INC. (US) | 1999-05-25 | — | — | US | disclosed |
| US-5834607-A | FOR ENHANCED CELLULAR UPTAKE OF OLIGONUCLEOTIDES; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5591841-A | REVERSIBLY FORMING A TRIPLE STRANDED STRUCTURE, ELIMINATES NEED FOR DENATURING | UNITED STATES DEPARTMENT OF ENERGY | 1997-01-07 | — | — | US | disclosed |
| WO-1994006815-A1 | OLIGONUCLEOTIDE AND NUCLEOTIDE AMINE ANALOGS, METHODS OF SYNTHESIS AND USE | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RBM22, RNGTT, RBM25 | ATAD2 3454/4885DPYD 4273/4885ALDH1A1 4880/4885 |
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNGTT, SARS1, ACE2 | ATAD2 3075/4885DPYD 3228/4885ALDH1A1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.